Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/10/2019
SIETES contiene 92826 citas

 
 
 1 a 20 de 135 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
2. Cita con resumen
Anónimo. Maladies auto-immunes d'origine médicamenteuse. Prescrire 2017;37:346-53. [Ref.ID 101654]
3.Tiene citas relacionadas Cita con resumen
Schoenfeld AJ, Redberg RF. The value of using registries to evaluate randomized clinical trial study populations. JAMA Intern Med 2017;177:889. [Ref.ID 101623]
4.Tiene citas relacionadas Cita con resumen
Maddox TM, Tang F, Downs JR, Masoudi FA, Virani SS, Daugherty SL, Rumsfeld JS. Applicability of the IMPROVE-IT trial to current patients with acute coronary syndrome: an NCDR research to practice project. JAMA Intern Med 2017;177:887-9. [Ref.ID 101622]
5. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
6. Cita con resumen
Anónimo. Lipid-lowering drugs. Med Lett Drugs Ther 2016;58:133-40. [Ref.ID 100944]
7. Cita con resumen
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97. [Ref.ID 100769]
8. Cita con resumen
Anónimo. Alirocumab. Prescrire 2016;36:331-2. [Ref.ID 100534]
9. Cita con resumen
Anónimo. Évolocumab. Prescrire 2016;36:326-31. [Ref.ID 100533]
10.Tiene citas relacionadas Cita con resumen
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, for the GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. The GAUSS-3 randomized clinical trial. JAMA 2016;315:1580-90. [Ref.ID 100239]
11.Tiene citas relacionadas Cita con resumen
Waters DD, Hsue PY, Bangalore S. PCSK9 inhibitors for statin intolerance?. JAMA 2016;315:1571-2. [Ref.ID 100238]
12. Cita con resumen
Pintó X, García Gómez MC. Nuevos tratamientos para la hipercolesterolemia. Med Clin (Barc) 2016;146:172-7. [Ref.ID 100102]
13. Cita con resumen
Anónimo. Un médecin italien intimidé par une firme: un air de déjà vu. Prescrire 2015;35:543. [Ref.ID 99442]
14. Cita con resumen
Jarcho JA, Keaney JF Jr. Proof that lower is better - LDL cholesterol and IMPROVE-it. N Engl J Med 2015;372:2448-58. [Ref.ID 99299]
15. Cita con resumen
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzylio W, De Lucca P, Im K, Bohula EA, Reist CJ, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. [Ref.ID 99298]
16. Cita con resumen
Anónimo. Adding ezetimibe to statin therapy may reduce CV events in high-risk patients with ACS. DIA Daily 2014:18 de noviembre. [Ref.ID 98333]
17. Cita con resumen
Ross JS, Frazee SG, Garavaglia SB, Levin R, Novshadian H, Jackevicius CA, Stettin G, Krumholz HM. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. JAMA Intern Med 2014;174:1486-93. [Ref.ID 97900]
18. Cita con resumen
Turone F. MSD "regrets" tactics used to silence doctor over prescription advice. BMJ 2014;349:g4599. [Ref.ID 97757]
19. Cita con resumen
Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. A systematic review. Ann Intern Med 2014;160:468-76. [Ref.ID 97523]
20.Enlace a cita original
Tonelli M, Wanner Ch, for the Kidney disease: improving global outcomes lipid guideline development work group members. Lipid management in chronick Kidney disease: synopsis of the Kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182-93. [Ref.ID 97317]
Seleccionar todas
 
 1 a 20 de 135 siguiente >>